XOMA to Announce Fourth Quarter and Full Year 2015 Financial Results and Host Webcast on March 9
March 09 2016 - 07:46PM
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and
development of antibody therapeutics, announced the Company will
host a conference call on Wednesday, March 9, 2016, at 4:30 p.m.
Eastern Standard Time to discuss fourth quarter and full year 2015
financial results and provide an update on its endocrine disease
portfolio.
The webcast can be accessed via the Investors
& Media section of XOMA's website at
http://investors.xoma.com/events.cfm and will be available for
replay until close of business on May 9, 2016. Telephone numbers
for the live audiocast are 877-369-6589 (U.S./Canada) and
408-337-0122 (international).
About XOMA CorporationXOMA
Corporation is a leader in the discovery and development of
therapeutic antibodies. The Company's innovative product candidates
result from its expertise in developing ground-breaking monoclonal
antibodies, including allosteric antibodies, which have created new
opportunities to potentially treat a wide range of human diseases.
XOMA's scientific research has produced a portfolio of five
endocrine assets, each of which has the opportunity to address
multiple indications. The Company's lead product candidate, XOMA
358, is an allosteric monoclonal antibody that reduces insulin
receptor activity, which could have a major impact on the treatment
of hyperinsulinism. The Company recently initiated Phase 2
development activities for XOMA 358 in patients with congenital
hyperinsulinism. For more information, visit www.xoma.com.
CONTACT: Investor Contacts:
Ashleigh Barreto, XOMA
510-204-7482
barreto@xoma.com
Juliane Snowden, The Oratorium Group, LLC
jsnowden@oratoriumgroup.com
Media Contact:
Ryan Flinn, W2O Group
415-946-1059
rflinn@w2ogroup.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Feb 2024 to Mar 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2023 to Mar 2024